Avalon Pharmaceuticals Receives Audit Opinion Containing Going Concern Statement

* Reuters is not responsible for the content in this press release.

Tue Apr 7, 2009 3:00pm EDT 

GERMANTOWN, Md.--(Business Wire)--
Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced, in compliance with
NASDAQ Marketplace Rule 4350(b)(1)(B), that the independent audit report
included in the Company`s Annual Report on Form 10-K for the fiscal year ended
December 31, 2008 contained an unqualified audit opinion from its independent
public accounting firm, Ernst & Young LLP, which included a "going concern"
explanatory statement. This disclosure is required under NASDAQ rules and does
not represent any change to the Company`s Annual Report on Form 10-K for the
year ended December 31, 2008 which was filed on March 31, 2009 with the
Securities and Exchange Commission. 

About Avalon Pharmaceuticals

Avalon is a biopharmaceutical company focused on the discovery, development and
commercialization of first-in-class cancer therapeutics. 



Avalon Pharmaceuticals, Inc.
C. Eric Winzer
Executive Vice President & Chief Financial Officer
301-556-9900
Fax: 301-556-9910
info@avalonrx.com



Copyright Business Wire 2009
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.